NATERA INC (NTRA) Fundamental Analysis & Valuation

NASDAQ:NTRA • US6323071042

Current stock price

198.38 USD
+0.7 (+0.35%)
At close:
198.38 USD
0 (0%)
After Hours:

This NTRA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

3

1. NTRA Profitability Analysis

1.1 Basic Checks

  • NTRA had negative earnings in the past year.
  • NTRA had a positive operating cash flow in the past year.
  • In the past 5 years NTRA always reported negative net income.
  • In multiple years NTRA reported negative operating cash flow during the last 5 years.
NTRA Yearly Net Income VS EBIT VS OCF VS FCFNTRA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M -400M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -8.68%, NTRA belongs to the top of the industry, outperforming 83.78% of the companies in the same industry.
  • NTRA has a better Return On Equity (-12.16%) than 85.71% of its industry peers.
Industry RankSector Rank
ROA -8.68%
ROE -12.16%
ROIC N/A
ROA(3y)-16.77%
ROA(5y)-25.55%
ROE(3y)-28.3%
ROE(5y)-46.95%
ROIC(3y)N/A
ROIC(5y)N/A
NTRA Yearly ROA, ROE, ROICNTRA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -100 -200 -300 -400 -500

1.3 Margins

  • NTRA has a better Gross Margin (64.75%) than 79.15% of its industry peers.
  • NTRA's Gross Margin has improved in the last couple of years.
  • NTRA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 64.75%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y13.42%
GM growth 5Y6.2%
NTRA Yearly Profit, Operating, Gross MarginsNTRA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. NTRA Health Analysis

2.1 Basic Checks

  • NTRA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • NTRA has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for NTRA has been increased compared to 5 years ago.
  • NTRA has a better debt/assets ratio than last year.
NTRA Yearly Shares OutstandingNTRA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
NTRA Yearly Total Debt VS Total AssetsNTRA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B

2.2 Solvency

  • An Altman-Z score of 23.95 indicates that NTRA is not in any danger for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 23.95, NTRA belongs to the top of the industry, outperforming 90.54% of the companies in the same industry.
  • NTRA has a debt to FCF ratio of 1.06. This is a very positive value and a sign of high solvency as it would only need 1.06 years to pay back of all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 1.06, NTRA belongs to the top of the industry, outperforming 94.59% of the companies in the same industry.
  • NTRA has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.
  • NTRA has a Debt to Equity ratio of 0.05. This is comparable to the rest of the industry: NTRA outperforms 41.89% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF 1.06
Altman-Z 23.95
ROIC/WACCN/A
WACC8.91%
NTRA Yearly LT Debt VS Equity VS FCFNTRA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M 1B 1.5B

2.3 Liquidity

  • NTRA has a Current Ratio of 3.39. This indicates that NTRA is financially healthy and has no problem in meeting its short term obligations.
  • NTRA has a worse Current ratio (3.39) than 60.23% of its industry peers.
  • NTRA has a Quick Ratio of 3.24. This indicates that NTRA is financially healthy and has no problem in meeting its short term obligations.
  • With a Quick ratio value of 3.24, NTRA is not doing good in the industry: 60.81% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 3.39
Quick Ratio 3.24
NTRA Yearly Current Assets VS Current LiabilitesNTRA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. NTRA Growth Analysis

3.1 Past

  • NTRA shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 0.65%.
  • The Revenue has grown by 35.90% in the past year. This is a very strong growth!
  • NTRA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 42.61% yearly.
EPS 1Y (TTM)0.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%187.8%
Revenue 1Y (TTM)35.9%
Revenue growth 3Y41.14%
Revenue growth 5Y42.61%
Sales Q2Q%39.78%

3.2 Future

  • Based on estimates for the next years, NTRA will show a very strong growth in Earnings Per Share. The EPS will grow by 37.27% on average per year.
  • NTRA is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 17.55% yearly.
EPS Next Y-25.06%
EPS Next 2Y32.85%
EPS Next 3Y40.11%
EPS Next 5Y37.27%
Revenue Next Year18.14%
Revenue Next 2Y18.68%
Revenue Next 3Y19.28%
Revenue Next 5Y17.55%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
NTRA Yearly Revenue VS EstimatesNTRA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2B 4B 6B
NTRA Yearly EPS VS EstimatesNTRA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 5 -5 10

More info and screens

Find the best growth stocksShow best growing peers

2

4. NTRA Valuation Analysis

4.1 Price/Earnings Ratio

  • NTRA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NTRA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NTRA Price Earnings VS Forward Price EarningsNTRA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 -100

4.2 Price Multiples

  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of NTRA indicates a rather cheap valuation: NTRA is cheaper than 90.35% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 369.4
EV/EBITDA N/A
NTRA Per share dataNTRA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

  • NTRA's earnings are expected to grow with 40.11% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.85%
EPS Next 3Y40.11%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. NTRA Dividend Analysis

5.1 Amount

  • No dividends for NTRA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

NTRA Fundamentals: All Metrics, Ratios and Statistics

NATERA INC

NASDAQ:NTRA (3/17/2026, 4:27:10 PM)

After market: 198.38 0 (0%)

198.38

+0.7 (+0.35%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26
Earnings (Next)05-06
Inst Owners93.51%
Inst Owner Change0.51%
Ins Owners3.04%
Ins Owner Change0.28%
Market Cap28.12B
Revenue(TTM)2.31B
Net Income(TTM)-208.16M
Analysts85
Price Target262.39 (32.27%)
Short Float %2.2%
Short Ratio2.52
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)50.47%
Min EPS beat(2)-68.19%
Max EPS beat(2)169.13%
EPS beat(4)2
Avg EPS beat(4)26.55%
Min EPS beat(4)-68.19%
Max EPS beat(4)169.13%
EPS beat(8)5
Avg EPS beat(8)29.82%
EPS beat(12)8
Avg EPS beat(12)21.96%
EPS beat(16)12
Avg EPS beat(16)18.12%
Revenue beat(2)2
Avg Revenue beat(2)11.68%
Min Revenue beat(2)10.13%
Max Revenue beat(2)13.23%
Revenue beat(4)4
Avg Revenue beat(4)11.53%
Min Revenue beat(4)10.13%
Max Revenue beat(4)13.23%
Revenue beat(8)8
Avg Revenue beat(8)13.31%
Revenue beat(12)12
Avg Revenue beat(12)10.39%
Revenue beat(16)14
Avg Revenue beat(16)8.14%
PT rev (1m)0.53%
PT rev (3m)10.6%
EPS NQ rev (1m)-3.59%
EPS NQ rev (3m)-7.75%
EPS NY rev (1m)1.17%
EPS NY rev (3m)-4.26%
Revenue NQ rev (1m)1.55%
Revenue NQ rev (3m)2.1%
Revenue NY rev (1m)1.39%
Revenue NY rev (3m)2.48%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 12.19
P/FCF 369.4
P/OCF 130.59
P/B 16.42
P/tB 23.48
EV/EBITDA N/A
EPS(TTM)-1.52
EYN/A
EPS(NY)-1.9
Fwd EYN/A
FCF(TTM)0.54
FCFY0.27%
OCF(TTM)1.52
OCFY0.77%
SpS16.27
BVpS12.08
TBVpS8.45
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -8.68%
ROE -12.16%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 64.75%
FCFM 3.3%
ROA(3y)-16.77%
ROA(5y)-25.55%
ROE(3y)-28.3%
ROE(5y)-46.95%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y13.42%
GM growth 5Y6.2%
F-Score5
Asset Turnover0.96
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF 1.06
Debt/EBITDA N/A
Cap/Depr 320.09%
Cap/Sales 6.04%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.39
Quick Ratio 3.24
Altman-Z 23.95
F-Score5
WACC8.91%
ROIC/WACCN/A
Cap/Depr(3y)243.71%
Cap/Depr(5y)291.51%
Cap/Sales(3y)4.73%
Cap/Sales(5y)5.59%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%187.8%
EPS Next Y-25.06%
EPS Next 2Y32.85%
EPS Next 3Y40.11%
EPS Next 5Y37.27%
Revenue 1Y (TTM)35.9%
Revenue growth 3Y41.14%
Revenue growth 5Y42.61%
Sales Q2Q%39.78%
Revenue Next Year18.14%
Revenue Next 2Y18.68%
Revenue Next 3Y19.28%
Revenue Next 5Y17.55%
EBIT growth 1Y-39.41%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year34.47%
EBIT Next 3Y41.8%
EBIT Next 5Y29.98%
FCF growth 1Y29.56%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y58.7%
OCF growth 3YN/A
OCF growth 5YN/A

NATERA INC / NTRA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of NATERA INC (NTRA) stock?

ChartMill assigns a fundamental rating of 4 / 10 to NTRA.


What is the valuation status of NATERA INC (NTRA) stock?

ChartMill assigns a valuation rating of 2 / 10 to NATERA INC (NTRA). This can be considered as Overvalued.


How profitable is NATERA INC (NTRA) stock?

NATERA INC (NTRA) has a profitability rating of 3 / 10.


How financially healthy is NATERA INC?

The financial health rating of NATERA INC (NTRA) is 7 / 10.


What is the expected EPS growth for NATERA INC (NTRA) stock?

The Earnings per Share (EPS) of NATERA INC (NTRA) is expected to decline by -25.06% in the next year.